Rice Hall James & Associates LLC Purchases New Shares in Sanuwave Health Inc. $SNWV

Rice Hall James & Associates LLC bought a new position in shares of Sanuwave Health Inc. (NASDAQ:SNWV) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 27,302 shares of the company’s stock, valued at approximately $1,023,000. Rice Hall James & Associates LLC owned approximately 0.32% of Sanuwave Health as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Farther Finance Advisors LLC acquired a new position in Sanuwave Health in the 3rd quarter worth about $57,000. Stonebridge Wealth Management LLC purchased a new stake in shares of Sanuwave Health in the second quarter valued at approximately $1,696,000. Opaleye Management Inc. raised its stake in shares of Sanuwave Health by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 980,000 shares of the company’s stock worth $32,203,000 after buying an additional 7,998 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Sanuwave Health during the 2nd quarter valued at approximately $738,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Sanuwave Health during the 2nd quarter valued at approximately $46,000. 42.53% of the stock is currently owned by institutional investors and hedge funds.

Sanuwave Health Price Performance

SNWV opened at $30.49 on Friday. The firm has a market capitalization of $261.60 million, a price-to-earnings ratio of -23.45 and a beta of 1.32. The company’s 50 day simple moving average is $31.62 and its two-hundred day simple moving average is $34.40. Sanuwave Health Inc. has a 1-year low of $20.50 and a 1-year high of $46.58.

Sanuwave Health (NASDAQ:SNWV) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.14. The company had revenue of $11.45 million for the quarter.

Analyst Ratings Changes

SNWV has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Sanuwave Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Sanuwave Health in a research report on Wednesday, October 8th. Roth Capital set a $53.00 price target on shares of Sanuwave Health and gave the company a “buy” rating in a research note on Tuesday, October 7th. Northland Securities initiated coverage on Sanuwave Health in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $55.00 price objective for the company. Finally, Northland Capmk raised Sanuwave Health to a “strong-buy” rating in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $54.00.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.